Literature DB >> 17312995

Various tolerances to arsenic trioxide between human cortical neurons and leukemic cells.

Jin Zhou1, Ran Meng, Xinhua Sui, Wenbin Li, Baofeng Yang.   

Abstract

Arsenic trioxide (As2O3) is very effective for treatment of acute promyelocytic leukaemia (APL) but little can pass through the blood-brain-barrier (BBB), which limits its use in the prevention and treatment of central nervous system leukaemia (CNSL). Before creating a non-invasive method to help As2O3 's access, the safe and effective therapeutic concentration of As2O3 in the CNS ought to be known. The changes of apoptosis biomarkers, [Ca2+]i and PKC activity of both leukaemia cells and human cortical neurons, were monitored before and after being treated with As2O3 in vitro with laser confocal microscopy and Western blot. NSE concentration, the neuron invasive biomarker, was monitored by enzyme immunoassay (NSE-EIA). This study revealed that cortical neuron was more tolerable to As2O3 compared to NB4. 1.0 micromol / L As2O3 showed little influence on cortical neuron but effectively promoted apoptosis and induced differentiation of NB4.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17312995     DOI: 10.1007/s11427-006-2034-x

Source DB:  PubMed          Journal:  Sci China C Life Sci        ISSN: 1006-9305


  5 in total

1.  Arsenic trioxide and mannitol for the treatment of acute promyelocytic leukemia relapse in the central nervous system.

Authors:  Hong Wang; Fenglin Cao; Jinmei Li; Limin Li; Yong Li; Ce Shi; Wenjia Lan; Dandan Li; Hui Zhao; Ying Zhang; Zhuo Zhang; Xiuhua Liu; Ran Meng; Baofeng Yang; Jin Zhou
Journal:  Blood       Date:  2014-06-24       Impact factor: 22.113

2.  Arsenate stimulates glutathione export from viable cultured rat cerebellar granule neurons.

Authors:  Michaela C Hohnholt; Eva-Maria Blumrich; Yvonne Koehler; Ralf Dringen
Journal:  Neurochem Res       Date:  2014-12-12       Impact factor: 3.996

3.  Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy.

Authors:  Claudia Paret; Johanna Theruvath; Alexandra Russo; Bettina Kron; Khalifa El Malki; Nadine Lehmann; Arthur Wingerter; Marie A Neu; Aslihan Gerhold-Ay; Wolfgang Wagner; Clemens Sommer; Torsten Pietsch; Larissa Seidmann; Jörg Faber
Journal:  Oncotarget       Date:  2016-12-13

4.  A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system.

Authors:  Yanping Lu; Shunping Han; Hongyue Zheng; Rui Ma; Yuting Ping; Jiafeng Zou; Hongxia Tang; Yongping Zhang; Xiuling Xu; Fanzhu Li
Journal:  Int J Nanomedicine       Date:  2018-10-02

5.  Personalized therapy: CNS HGNET-BCOR responsiveness to arsenic trioxide combined with radiotherapy.

Authors:  Claudia Paret; Alexandra Russo; Henrike Otto; Arnulf Mayer; Sebastian Zahnreich; Wolfgang Wagner; David Samuel; David Scharnhorst; David A Solomon; Girish Dhall; Kenneth Wong; Hannah Bender; Francesca Alt; Arthur Wingerter; Marie A Neu; Olaf Beck; Dirk Prawitt; Stefan Eder; Nicole Henninger; Khalifa El Malki; Nadine Lehmann; Nora Backes; Lea Roth; Larissa Seidmann; Clemens Sommer; Marc A Brockmann; Gundula Staatz; Heinz Schmidberger; Jörg Faber
Journal:  Oncotarget       Date:  2017-12-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.